BioView, Abbott extend cancer diagnostics collaboration

Bioview will develop in automated cancer screening system to carry out Abbott Molecular's lung cancer diagnostic test.

Cancer screening company BioView Ltd. (TASE:BIOV) has signed a cooperation agreement with Abbott Molecular Inc., under which Bioview will develop in automated cancer screening system to carry out Abbott's lung cancer diagnostic test.

Abbott Molecular's current test to distinguish between different kinds of lung cancer, in order to provide the proper treatment, is carried out manually by a laboratory technician. Automating the test will save time and effort, and improve accuracy.

BioView has already applied its technology to other Abbott Molecular tests for breast and bladder cancer. Each time that these tests were approved, they boosted BioView's sales by millions of dollars.

Under the new collaboration, the two companies will jointly conduct clinical trials of the automated lung cancer test in order to certify it for marketing in the US. Abbott's manual test is already certified by the US Food and Drug Administration (FDA). The companies estimate that this process will take several months.

Published by Globes [online], Israel business news - - on November 28, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017